000			nab a22 7a 4500
999			_c62239 _d62231
001			62239
003			MX-TxCIM
005			20200713222420.0
008			200124s2014 xxk|||p|op||| 00| 0 eng d
022			_a0963-7486
022			_a1465-3478 (Online)
024	8		_ahttps://doi.org/10.3109/09637486.2014.898260
040			_aMX-TxCIM
041			_aeng
100	1		_914610 _aBarnett, M.P.G.
245	1	0	_aDietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats
260			_aUnited Kingdom : _bTaylor and Francis, _c2014.
500			_aPeer review
520			_aWe compared the gastrointestinal effects of milk-based diets in which the β-casein component was either the A1 or A2 type in male Wistar rats fed the experimental diets for 36 or 84 h. Gastrointestinal transit time was significantly greater in the A1 group, as measured by titanium dioxide recovery in the last 24 h of feeding. Co-administration of naloxone decreased gastrointestinal transit time in the A1 diet group but not in the A2 diet group. Colonic myeloperoxidase and jejunal dipeptidyl peptidase (DPP)-4 activities were greater in the A1 group than in the A2 group. Naloxone attenuated the increase in myeloperoxidase activity but not that in DPP-4 activity in the A1 group. Naloxone did not affect myeloperoxidase activity or DPP-4 activity in the A2 group. These results confirm that A1 β-casein consumption has direct effects on gastrointestinal function via opioid-dependent (gastrointestinal transit and myeloperoxidase activity) and opioid-independent (DPP-4 activity) pathways.
546			_aText in English
650		7	_2AGROVOC _914611 _aBeta-casein
650		7	_2AGROVOC _914612 _aCow milk
650		7	_2AGROVOC _914613 _aGastrointestinal motility
700	1		_914614 _aMcNabb, W.C.
700	1		_914615 _aRoy, N.C.
700	1		_914616 _aWoodford, K.B.
700	1		_914617 _aClarke, A.J.
773	0		_dUnited Kingdom : Taylor and Francis, 2014. _gv. 65, no. 6, p. 720-727 _tInternational Journal of Food Sciences and Nutrition _x0963-7486
942			_2ddc _cJA _n0